Abstract: The present invention relates to a process for the preparation of acetyl-amidiniophenylalanyl-cyclohexylglycyl-pyridinioalaninamides of the formula I, 1
Type:
Application
Filed:
June 17, 2004
Publication date:
November 11, 2004
Applicant:
Aventis Pharma Deutschland GmbH
Inventors:
Gerhard Breipohl, Wolfgang Holla, Heiner Jendralla, Gerhard Beck
Abstract: Cyclic and heterocyclic N-substituted &agr;-iminohydroxamic and -carboxylic acids
Compounds of the formula I
are suitable for preparing pharmaceuticals for the treatment of disorders in the course of which is involved an increased activity of matrix-degrading metalloproteinases.
Abstract: The invention relates to arylcycloalkyl-substituted derivatives and to their physiologically acceptable salts and physiologically functional derivatives.
Type:
Application
Filed:
February 27, 2004
Publication date:
November 4, 2004
Applicant:
Aventis Pharma Deutschland GmbH
Inventors:
Christian Stapper, Heiner Glombik, Eugen Falk, Dirk Gretzke, Jochen Goerlitzer, Stefanie Keil, Hans-Ludwig Schaefer, Wolfgang Wendler
Abstract: The invention relates to substituted N-aryl heterocycles and to the physiologically tolerated salts and physiologically functional derivatives thereof.
Type:
Application
Filed:
February 17, 2004
Publication date:
November 4, 2004
Applicant:
Aventis Pharma Deutschland GmbH
Inventors:
Lothar Schwink, Siegfried Stengelin, Matthias Gossel, Thomas Boehme, Gerhard Hessler, Petra Stahl, Dirk Gretzke
Abstract: Polysubstituted indan-1-ol compounds of formula I, its physiologically acceptable salts and physiologically functional derivatives are disclosed
Compositions comprising the same, methods of preparation and methods for the prophylaxis or treatment of obesity are also disclosed herein.
Type:
Grant
Filed:
October 27, 2003
Date of Patent:
November 2, 2004
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
Abstract: The invention relates to carboxamide-substituted phenylurea derivatives and their physiologically tolerated salts and physiologically functional derivatives.
Compounds of the formula I
in which the radicals have the stated meanings, and the physiologically tolerated salts thereof and process for their preparation are described. The compounds are suitable, for example, for treating type II diabetes.
Type:
Grant
Filed:
May 24, 2002
Date of Patent:
November 2, 2004
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Elisabeth Defossa, Thomas Klabunde, Hans-Joerg Burger, Andreas Herling, Erich von Roedern, Stefan Peukert, Alfons Enhsen, Armin Bauer, Bernd Neises, Karl Ulrich Wendt
Abstract: The present invention relates to the method of stimulating the expression of endothelial NO-synthase in a mammal, which method comprises administering a physiologically active amount of 4-fluoro-N-indan-2-yl benzamide according to the formula (I)
to the said mammal.
Type:
Grant
Filed:
July 22, 2003
Date of Patent:
November 2, 2004
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Paulus Wohlfart, Teri Suzuki, Ramalinga M. Dharanipragada, Alena Safarova, Armin Walser, Hartmut Strobel
Abstract: Polysubstituted indan-1-ol compounds of formula I, its physiologically acceptable salts and physiologically functional derivatives are disclosed
Compositions comprising the same, methods of preparation and methods for the prophylaxis or treatment of obesity are also disclosed herein.
Type:
Grant
Filed:
October 27, 2003
Date of Patent:
November 2, 2004
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Gerhard Jaehne, Volker Krone, Martin Bickel, Matthias Gossel
Abstract: The present invention relates to 3-guanidinocarbonyl-1-heteroaryl-indole derivatives, pharmaceutical compositions comprising such derivatives, methods of treatment comprising administering such derivatives, and processes for their preparation.
Abstract: The invention relates to a process for the conversion of echinocandin class of peptides to their C4-homotyrosine monodeoxy analogues, particularly mulundocandin to deoxymulundocandin, which consists of a single step selective reduction of C4-htyr (homotyrosine) hydroxyl group of echinocandins to their monodeoxy analogues under neutral conditions without prior protection/deprotection of the equally facile C5-Orn (ornithine) hydroxyl group and purification of the monodeoxy compound from the crude reaction mixture.
Abstract: The present invention relates to compounds of the formula I
in which A1, A2, R2 and R3 have the meanings indicated in the claims, which are valuable pharmaceutical active compounds for the therapy and prophylaxis of diseases, for example of cardiovascular disorders such as high blood pressure, angina pectoris, cardiac insufficiency, thromboses or atherosclerosis. The compounds of the formula I have the ability to modulate the endogenous production of cyclic guanosine monophosphate (cGMP) and are generally suitable for the therapy and prophylaxis of disease states which are associated with a disturbed cGMP balance. The invention relates to the use of compounds of the formula I for the therapy and prophylaxis of the designated disease states and for the production of pharmaceuticals therefor, novel compounds of the formula I, pharmaceutical preparations comprising them and processes for their preparation.
Type:
Grant
Filed:
January 24, 2003
Date of Patent:
October 26, 2004
Assignee:
Aventis Pharma Deutschland GmbH
Inventors:
Ursula Schindler, Karl Schoenafinger, Hartmut Strobel
Abstract: The present invention provides various processes for the preparation of (R)-&agr;-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol.
Type:
Application
Filed:
May 4, 2004
Publication date:
October 21, 2004
Applicants:
Aventis Pharmaceuticals Inc., Aventis Pharma Deutschland GmbH
Inventors:
Thomas Heinz Eduard Hilpert, Hans-Wolfram Flemming, Sandra K. Stolz-Dunn, Jonathan C. Evans, Ian A. Tomlinson
Abstract: The invention relates to 1,3-substituted cycloalkyl derivatives having acidic, mostly heterocyclic groups and to their physiologically acceptable salts and physiologically functional derivatives.
Type:
Application
Filed:
February 27, 2004
Publication date:
October 21, 2004
Applicant:
Aventis Pharma Deutschland GmbH
Inventors:
Jochen Goerlitzer, Heiner Glombik, Eugen Falk, Dirk Gretzke, Stefanie Keil, Hans-Ludwig Schaefer, Christian Stapper, Wolfgang Wendler